A study on the effect of switching prescription drugs to over-the-counter drugs (Switch OTC) on the willingness of allergic rhinitis patients to choose OTC medicines.

A study on the effect of converting prescription medications to over-the-counter medications (commonly known as Switch OTC) on the willingness of allergic rhinitis patients to choose OTC medications. - Hereafter referred to as the Switch OTC willingness Study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000058623

Enrollment

185

Registered

2025-07-29

Start date

2025-08-07

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

Group 1: No information provided by physicians

cost reduction amount = yen 0 (no discount). Group 2: No information provided by physicians

cost reduction amount = yen 1,000. Group 3: No information provided by physicians

cost reduction amount = yen 1,500. Group 4: Information provided via printed materials

cost reduction amount = yen 0 (no discount). Group 5: Information provided via printed materials

cost reduction amount = yen 1,000. Group 6: Information provided via printed materials

cost reduction amount = yen 1,500. Group 7: Information provided orally by physicians

cost reduction amount = yen 0 (no discount). Group 8: Information provided orally by physicians

cost reduction amount = yen 1,000. Group 9: Information provided orally by physicians

cost reduction amount = yen 1,500.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria are as follows: patients with a diagnosis of allergic rhinitis in their each medical claim data between January 1 and March 31 of 2024 or 2025, who are undergoing initial treatment, have mild symptoms, and do not meet any exclusion criteria. Written informed consent must be obtained. Eligible participants must be aged between 22 and 64 years at the time of consent, regardless of sex.

Exclusion criteria

Exclusion criteria: Exclusion criteria are based on the 2024 Guidelines for the Diagnosis and Treatment of Allergic Rhinitis, and include the following: patients with severe or most severe symptoms; patients with moderate symptoms; patients with mild symptoms using additional steroid nasal sprays; patients using medications containing ingredients not available in OTC drugs; and patients using ophthalmic solutions.

Design outcomes

Primary

Measure	Time frame
The primary outcome measure is the presence or absence of purchase intention for switch OTC products. as soon as possible.	—

Countries

Japan

Contacts

Public Contacttakamasa ikemoto

Graduate School of Health and Welfare, International University of Health and Welfare. Department of Healthcare and Welfare Management

24s3006@g.iuhw.ac.jp090-2164-4403

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026